Lonnel Coats's most recent trade in Blueprint Medicines Corp was a trade of 3,902 Common Stock done at an average price of $12812 . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 12812.00 per share. | 18 Jun 2025 | 3,902 | 6,144 (0%) | 0% | 12812 | 49,992,424 | Common Stock |
| Verve Therapeutics Inc | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 42,200 | 42,200 | - | - | Stock Option (right to buy) | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Sale of securities on an exchange or to another person at price $ 94.87 per share. | 20 Nov 2024 | 9,824 | 2,242 (0%) | 0% | 94.9 | 932,003 | Common Stock |
| Blueprint Medicines Corp | Lonnel Coats | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.79 per share. | 20 Nov 2024 | 7,500 | 20,754 (0%) | 0% | 69.8 | 523,425 | Common Stock |
| Blueprint Medicines Corp | Lonnel Coats | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2024 | 7,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Sale of securities on an exchange or to another person at price $ 94.24 per share. | 20 Nov 2024 | 5,287 | 12,279 (0%) | 0% | 94.2 | 498,247 | Common Stock |
| Blueprint Medicines Corp | Lonnel Coats | Director | Sale of securities on an exchange or to another person at price $ 93.15 per share. | 20 Nov 2024 | 4,500 | 17,566 (0%) | 0% | 93.2 | 419,175 | Common Stock |
| Blueprint Medicines Corp | Lonnel Coats | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2024 | 1,312 | 3,188 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 76.24 per share. | 20 Nov 2024 | 1,312 | 22,066 (0%) | 0% | 76.2 | 100,027 | Common Stock |
| Blueprint Medicines Corp | Lonnel Coats | Director | Sale of securities on an exchange or to another person at price $ 94.99 per share. | 20 Nov 2024 | 213 | 12,066 (0%) | 0% | 95.0 | 20,233 | Common Stock |
| Verve Therapeutics Inc | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 136,139 | 136,139 | - | - | Stock Option (right to buy) | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 4,570 | 4,570 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,242 | 13,254 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Coats Lonnel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 120,383 | 240,767 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 120,383 | 1,159,439 (1%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 91,364 | 91,363 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 91,364 | 1,039,056 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Coats Lonnel | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 61,371 | 1,098,068 (1%) | 0% | 2.6 | 160,792 | Common Stock |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,333 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Coats Lonnel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,333 | 947,692 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 770,420 | 770,420 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 770,420 | 770,420 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.16 per share. | 29 Jun 2023 | 10,000 | 814,359 (0%) | 0% | 2.2 | 21,600 | Common Stock |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 23 Jun 2023 | 10,000 | 794,359 (0%) | 0% | 2.5 | 24,950 | Common Stock |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.18 per share. | 23 Jun 2023 | 10,000 | 804,359 (0%) | 0% | 2.2 | 21,792 | Common Stock |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.31 per share. | 22 Jun 2023 | 40,000 | 784,359 (0%) | 0% | 2.3 | 92,400 | Common Stock |
| Blueprint Medicines Corp | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 2,600 | 11,012 (0%) | 0% | 0 | Common Stock | |
| Verve Therapeutics Inc | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,642 | 26,642 | - | - | Stock Option (right to buy) | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 91,363 | 795,330 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 91,363 | 182,727 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 84,630 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 84,630 | 670,633 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 50,971 | 744,359 (0%) | 0% | 2.2 | 110,607 | Common Stock |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 33,334 | 703,967 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 33,334 | 33,333 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 1,083,440 | 1,083,440 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 361,150 | 361,150 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 31,000 | 31,000 | - | - | Stock Option (right to buy) | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 2,600 | 8,412 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 84,630 | 600,723 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 84,630 | 84,630 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 79,380 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 79,380 | 516,093 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 48,053 | 586,003 (0%) | 0% | 2.8 | 136,951 | Common Stock |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 33,333 | 634,056 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 33,333 | 66,667 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 822,280 | 822,280 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 274,090 | 274,090 | - | - | Restricted Stock Units | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lonnel Coats | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,250 | 5,812 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 84,630 | 491,751 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 84,630 | 169,260 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 79,380 | 407,121 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 79,380 | 79,380 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 55,038 | 436,713 (0%) | 0% | 7.2 | 395,723 | Common Stock |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 23,513 | 327,741 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 23,513 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,362 | 304,228 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,362 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Lonnel Coats | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 100,000 | 100,000 | - | - | Restricted Stock Units |